about
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosisKidney dysfunction during lenalidomide treatment for AL amyloidosis.High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.A prospective study of nutritional status in immunoglobulin light chain amyloidosis.Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Systemic amyloidoses.Embryonic stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the differentiation potency in culture.Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.A Very Rare Presentation of Multiple Myeloma: Unilateral Raccoon Eye.A residue-specific shift in stability and amyloidogenicity of antibody variable domains.Current treatment of AL amyloidosis.Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.Case for diagnosis. Systemic light chain amyloidosis with cutaneous involvement.Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: The role of life satisfaction.Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies.Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.An unusual clinical course of cardiac Ig deposition disease.Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
P2860
Q33718805-A90F91A4-A886-4646-820C-95D2C086C0E6Q35025410-7694EDB5-4872-4C1D-ABF3-7274350572CBQ35750326-CA68E0E8-FCB9-4C4D-9066-F6B5FF665C4DQ36498408-757D0B32-F499-4252-BDDB-F0F595122B27Q36779759-E4CA4C3C-8B8B-4F7D-8DEA-37DBDC075740Q37676296-98AB8C74-694C-46B6-87EA-B3C40F91C269Q37999957-F12A5FBC-E885-4168-B9E1-E46BAC1C0367Q38085664-2A57EDB5-76FD-4E25-8567-1BB574B6FFF5Q39633631-6F8D2DCE-C78F-48E5-A519-C4862F9399F3Q41009910-45A01924-C508-464C-B546-CD4BB024F23AQ41877770-5367FD5E-5501-4C28-A032-CADB85409A53Q42028045-B8045279-D73D-4957-95CA-A1C59663DA26Q42662215-DDA66781-5C65-41BF-8500-63F63AD00329Q44248482-868DB9AA-0349-461B-B606-BE9413616781Q47177576-3E8DE74A-D3E8-4C14-BBF5-13DD979ED3BCQ48131698-498DA1F4-E78C-4B43-8070-61492FDF0C5AQ48467868-ED38FA7B-FE74-47A5-B6CE-615F8349112DQ48629376-4BD9B829-1E67-4AF9-B9E0-58CAB8414A6FQ51819753-21E87D8C-8C14-44AD-B81D-9124CC02A5B2Q58030146-BA8499AF-A13A-45B9-A801-DB38A1E57ED0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Amyloidosis: is a cure possible?
@en
Amyloidosis: is a cure possible?
@nl
type
label
Amyloidosis: is a cure possible?
@en
Amyloidosis: is a cure possible?
@nl
prefLabel
Amyloidosis: is a cure possible?
@en
Amyloidosis: is a cure possible?
@nl
P356
P1433
P1476
Amyloidosis: is a cure possible?
@en
P2093
G Palladini
P304
P356
10.1093/ANNONC/MDN200
P478
19 Suppl 4
P577
2008-06-01T00:00:00Z